




- Ovarian tumors with KRAS variant are resistant to treatment with standard chemotherapies including cisplatin
- Yale scientists have discovered that serotonin transport inhibitors selectively inhibit KRAS-variant ovarian cancer.
- This method can also be used to specifically treat other cancer, such as breast cancer, with KRAS-variant.
- **Intellectual property** patent application pending



Yale Contact: Hong Peng, Ph.D., Yale University Office of Cooperative Research
(203) 785-3074, hong.peng@yale.edu

